Nesrin Öcal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nesrin Öcal has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
- Deniz Doğan
UNIVERSITY OF HEALTH SCIENCES, GÜLHANE SCHOOL OF MEDICINE, GÜLHANE MEDICINE PR. (ANKARA)
9 shared publications - Cantürk Taşçı
Division of Pulmonology, Gulhane Faculty of Medicine & Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey
7 shared publications - Yakup Arslan
Department of Pulmonology Gülhane Education and Research Hospital, University of Health Sciences Ankara Türkiye
5 shared publications - Yakup Arslan
Kirklareli Universitesi
4 shared publications - Gülden Yılmaz
Gülhane Training and Research Hospital, University of Health Sciences
3 shared publications Ahmet Yurttas
Department of Pulmonary Medicine, Alanya Alaaddin Keykubat University School of Medicine, Antalya, Türkiye
2 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Springer Nature in Scientific Reports
Frailty, organ dysfunction and mortality in older ICU patients
- 25 August 2026
- Published by Springer Nature in Scientific Reports
Open AccessFrailty, organ dysfunction and mortality in older ICU patients
- Open Access
- 30 January 2026
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 27 (1) , 68-74
Turkish Thoracic Society Declaration on Peace and Health the Importance of Breathing in a World Without War
Turkish Thoracic Society Declaration on Peace and Health the Importance of Breathing in a World Without War - Thoracic Research and Practice
- 30 January 2026
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 27 (1) , 68-74
Open AccessTurkish Thoracic Society Declaration on Peace and Health the Importance of Breathing in a World Without War
Turkish Thoracic Society Declaration on Peace and Health the Importance of Breathing in a World Without War - Thoracic Research and Practice
- Open Access
- 29 November 2025
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 3 (4) , 102-107
Determinants of survival in acute pulmonary thromboembolism: real-life data from a 3-level health institution
Aims: Given that pulmonary thromboembolism is a prevalent cause of cardiovascular mortality, identifying quick and accessible diagnostic-prognostic markers for pulmonary thromboembolism may significantly contribute to mortality reduction. In this study, we aimed to determine to what extent diagnosis-prognosis markers of patients are predictive of survival, based on real-life data. Methods: Data from patients hospitalized with the diagnosis of pulmonary thromboembolism were retrospectively investigated. The demographic, clinical, and radiological findings were analyzed. Probability, severity, and mortality score determinations of patients with acute PE were analyzed using the Charlson Comorbidity Index, Pulmonary Embolism Severity Index, and Simplified Pulmonary Embolism Severity Index scores Results: The data of 300 patients were evaluated. The mortality rate was 11%. The patients' mean age was higher in the mortality group (p=0.035). In-hospital mortality was 7.3%, highest in the 9th and 6th decades (p=0.025 and p=0.036). The mortality rate was 26.6% in patients with thrombus in the pulmonary artery trunk (p=0.01). The presence of right heart strain on echocardiography was associated with mortality. (p0.05). Mortality frequency in the “high 30-day early mortality risk group” was significantly higher than others (p=0.02). Conclusion: Demographic and clinical characteristics are closely related to the survival of patients with pulmonary thromboembolism. An individual approach to patients diagnosed with pulmonary thromboembolism will provide management above all scores.
- 29 November 2025
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 3 (4) , 102-107
Open AccessDeterminants of survival in acute pulmonary thromboembolism: real-life data from a 3-level health institution
Aims: Given that pulmonary thromboembolism is a prevalent cause of cardiovascular mortality, identifying quick and accessible diagnostic-prognostic markers for pulmonary thromboembolism may significantly contribute to mortality reduction. In this study, we aimed to determine to what extent diagnosis-prognosis markers of patients are predictive of survival, based on real-life data. Methods: Data from patients hospitalized with the diagnosis of pulmonary thromboembolism were retrospectively investigated. The demographic, clinical, and radiological findings were analyzed. Probability, severity, and mortality score determinations of patients with acute PE were analyzed using the Charlson Comorbidity Index, Pulmonary Embolism Severity Index, and Simplified Pulmonary Embolism Severity Index scores Results: The data of 300 patients were evaluated. The mortality rate was 11%. The patients' mean age was higher in the mortality group (p=0.035). In-hospital mortality was 7.3%, highest in the 9th and 6th decades (p=0.025 and p=0.036). The mortality rate was 26.6% in patients with thrombus in the pulmonary artery trunk (p=0.01). The presence of right heart strain on echocardiography was associated with mortality. (p0.05). Mortality frequency in the “high 30-day early mortality risk group” was significantly higher than others (p=0.02). Conclusion: Demographic and clinical characteristics are closely related to the survival of patients with pulmonary thromboembolism. An individual approach to patients diagnosed with pulmonary thromboembolism will provide management above all scores.
- 10 June 2025
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 73 (2) , 151-155
A rare complication developing after endobronchial ultrasonography-guided transbronchial needle aspiration: Pneumomediastinum
- 10 June 2025
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 73 (2) , 151-155
A rare complication developing after endobronchial ultrasonography-guided transbronchial needle aspiration: Pneumomediastinum
- 5 December 2024
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 194 (1) , 391-397
Nintedanib and its combination with immunosuppressives in connective tissue disease-related interstitial lung diseases
Background Nintedanib reduces the decline of pulmonary function in patients with advancing lung fibrosis. Aim To assess the characteristics of the patients with connective tissue diseases (CTDs) related to interstitial lung disease (ILD) under nintedanib treatment. Methods The CTD-related ILD patients under nintedanib treatment who were followed up between 2020 and 2023 were included in the study. The clinical data of the patients before and after nintedanib were evaluated retrospectively. Results There were 36 patients (19 female) with a mean age of 65.2 ± 8.5 years who were treated with nintedanib. The median duration for nintedanib treatment was 19 months. The most common CTD was Sjogren’s syndrome (36.1%), followed by systemic sclerosis (27.8%), rheumatoid arthritis (25%), undifferentiated CTD (8.3%), and inflammatory myositis (2.8%). Fifteen (41.7%) patients had impaired pulmonary function tests (FVC < 70 ml and/or DLco < 80 ml), and 23 (63.9%) patients had ≥ 20% involvement of parenchyma in high-resolution computed tomography (HRCT) before nintedanib. According to HRCT findings, 25 (69.4%) patients had the usual interstitial pneumonia pattern. All patients had 300 mg/day of nintedanib and received at least one immunosuppressive treatment during the study period. The mean %predicted value of FVC was 82.8 ± 17.6, and DLco was 65.3 ± 19.2 before nintedanib treatment. Following the 6-month follow-up, FVC showed an increase to 92.3 ± 15.8 (with an R correlation coefficient of 0.54, p = 0.025), and 22 (61.1%) patients exhibited either stabilization or regression of findings on HRCT. Conclusions Nintedanib emerges as a promising therapeutic agent compatible with immunosuppressives for treating progressive lung fibrosis in patients with CTD-related ILD.
- 5 December 2024
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 194 (1) , 391-397
Nintedanib and its combination with immunosuppressives in connective tissue disease-related interstitial lung diseases
Background Nintedanib reduces the decline of pulmonary function in patients with advancing lung fibrosis. Aim To assess the characteristics of the patients with connective tissue diseases (CTDs) related to interstitial lung disease (ILD) under nintedanib treatment. Methods The CTD-related ILD patients under nintedanib treatment who were followed up between 2020 and 2023 were included in the study. The clinical data of the patients before and after nintedanib were evaluated retrospectively. Results There were 36 patients (19 female) with a mean age of 65.2 ± 8.5 years who were treated with nintedanib. The median duration for nintedanib treatment was 19 months. The most common CTD was Sjogren’s syndrome (36.1%), followed by systemic sclerosis (27.8%), rheumatoid arthritis (25%), undifferentiated CTD (8.3%), and inflammatory myositis (2.8%). Fifteen (41.7%) patients had impaired pulmonary function tests (FVC < 70 ml and/or DLco < 80 ml), and 23 (63.9%) patients had ≥ 20% involvement of parenchyma in high-resolution computed tomography (HRCT) before nintedanib. According to HRCT findings, 25 (69.4%) patients had the usual interstitial pneumonia pattern. All patients had 300 mg/day of nintedanib and received at least one immunosuppressive treatment during the study period. The mean %predicted value of FVC was 82.8 ± 17.6, and DLco was 65.3 ± 19.2 before nintedanib treatment. Following the 6-month follow-up, FVC showed an increase to 92.3 ± 15.8 (with an R correlation coefficient of 0.54, p = 0.025), and 22 (61.1%) patients exhibited either stabilization or regression of findings on HRCT. Conclusions Nintedanib emerges as a promising therapeutic agent compatible with immunosuppressives for treating progressive lung fibrosis in patients with CTD-related ILD.
- 2 September 2024
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 13 (5) , tfae177
Effects of Immunotoxicity biomarkers, essential elements and vitamin D levels on the severity levels of COVID-19 disease in Turkey
Many mechanisms are thought to play a role in the pathogenesis of the COVID-19 pandemic, which started in 2019 and affected the whole world. It has been claimed that a deficiency in the immune system can significantly affect the severity of COVID-19 disease. It is important that the levels of essential elements and vitamin D are at certain levels for the healthy functioning of the immune system. Therefore, in this study, it was aimed to evaluate immunotoxicity biomarkers (tumor necrosis factor-alpha (TNF-α), interleukin (IL)-10, interferon (IFN)-γ, monocyte chemotactic protein-1 (MCP-1)), vitamin D, and essential element levels in COVID-19 patients in Turkey. According to the results of the study, it was found that the magnesium (Mg), zinc (Zn), and selenium (Se) levels decreased as the severity of the disease worsened, while the iron (Fe), and copper (Cu) levels were similar to the mild group and the control group, and the levels decreased as the disease worsened. It has also been found that vitamin D levels decrease as the severity of the disease worsens. Compared to the control group, TNF-α, MCP-1, and IFN-γ levels were found to decrease as the severity of the disease worsened. Also, it was observed that there was a significant relationship between essential metal levels and disease progression in most of the patient groups.
- 2 September 2024
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 13 (5) , tfae177
Effects of Immunotoxicity biomarkers, essential elements and vitamin D levels on the severity levels of COVID-19 disease in Turkey
Many mechanisms are thought to play a role in the pathogenesis of the COVID-19 pandemic, which started in 2019 and affected the whole world. It has been claimed that a deficiency in the immune system can significantly affect the severity of COVID-19 disease. It is important that the levels of essential elements and vitamin D are at certain levels for the healthy functioning of the immune system. Therefore, in this study, it was aimed to evaluate immunotoxicity biomarkers (tumor necrosis factor-alpha (TNF-α), interleukin (IL)-10, interferon (IFN)-γ, monocyte chemotactic protein-1 (MCP-1)), vitamin D, and essential element levels in COVID-19 patients in Turkey. According to the results of the study, it was found that the magnesium (Mg), zinc (Zn), and selenium (Se) levels decreased as the severity of the disease worsened, while the iron (Fe), and copper (Cu) levels were similar to the mild group and the control group, and the levels decreased as the disease worsened. It has also been found that vitamin D levels decrease as the severity of the disease worsens. Compared to the control group, TNF-α, MCP-1, and IFN-γ levels were found to decrease as the severity of the disease worsened. Also, it was observed that there was a significant relationship between essential metal levels and disease progression in most of the patient groups.
- Open Access
- 11 June 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (2) , 137-144
Retrospective evaluation of the effects of pulmonary artery and aortic diameters on hospitalization duration and survival in patients hospitalized with COVID-19
Retrospective evaluation of the effects of pulmonary artery and aortic diameters on hospitalization duration and survival in patients hospitalized with COVID-19 Introduction: This study explores the impact of vascular diameters on mortality risk in Coronavirus disease -2019 (COVID-19) patients. COVID-19, caused by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), presents diverse clinical manifestations and is associated with thrombosis. Materials and Methods: In this study, we retrospectively examined the data of patients who were hospitalized and treated in our hospital between September 1, 2020, and November 30, 2020, and whose COVID-19 diagnosis was confirmed by reverse transcriptase polymerase chain reaction (RT-PCR). The diameters of the ascending aorta, main pulmonary artery, and right and left pulmonary arteries were measured from the chest computed tomography (CT) scans taken at the time of admission. The aim of the study was to investigate the impact of vascular diameters on the course of the disease. Results: Of 1.705 patients, 840 were eligible for the study. We concluded that 36 of the patients (4.3%) died, and among the non -survivors patients, 12 (33.3%) were females, and 24 (66.7%) were males. Hospitalization duration was 7.1 +/- 3.1 vs. 6.1 +/- 2 days (p= 0.004) in surviving and non -surviving patients respectively. On the other hand, we found the mean diameters of the right pulmonary artery in the chest CT of patients to be 2.17 +/- 0.35 vs. 2.44 +/- 0.29 cm in survivors and non -survivors, respectively (p< 0.001). In addition, we found the mean diameters of the left pulmonary artery 2.12 +/- 0.32 vs. 2.34 +/- 0.28 cm in survivors and non -survivors, respectively (p< 0.001). Mean diameters of the ascending aorta were 3.53 +/- 0.46 vs. 3.72 +/- 0.34 cm in survivors and non -survivors, respectively (p= 0.017). Conclusion: The study underscores the potential prognostic value of vascular diameters, especially in the ascending aorta and main pulmonary artery, as indicators of mortality risk in COVID-19 patients. The association between vascular dilation and severity of COVID-19, coupled with elevated D-dimer levels, suggests a link between thrombosis and vascular involvement.
- 11 June 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (2) , 137-144
Open AccessRetrospective evaluation of the effects of pulmonary artery and aortic diameters on hospitalization duration and survival in patients hospitalized with COVID-19
Retrospective evaluation of the effects of pulmonary artery and aortic diameters on hospitalization duration and survival in patients hospitalized with COVID-19 Introduction: This study explores the impact of vascular diameters on mortality risk in Coronavirus disease -2019 (COVID-19) patients. COVID-19, caused by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), presents diverse clinical manifestations and is associated with thrombosis. Materials and Methods: In this study, we retrospectively examined the data of patients who were hospitalized and treated in our hospital between September 1, 2020, and November 30, 2020, and whose COVID-19 diagnosis was confirmed by reverse transcriptase polymerase chain reaction (RT-PCR). The diameters of the ascending aorta, main pulmonary artery, and right and left pulmonary arteries were measured from the chest computed tomography (CT) scans taken at the time of admission. The aim of the study was to investigate the impact of vascular diameters on the course of the disease. Results: Of 1.705 patients, 840 were eligible for the study. We concluded that 36 of the patients (4.3%) died, and among the non -survivors patients, 12 (33.3%) were females, and 24 (66.7%) were males. Hospitalization duration was 7.1 +/- 3.1 vs. 6.1 +/- 2 days (p= 0.004) in surviving and non -surviving patients respectively. On the other hand, we found the mean diameters of the right pulmonary artery in the chest CT of patients to be 2.17 +/- 0.35 vs. 2.44 +/- 0.29 cm in survivors and non -survivors, respectively (p< 0.001). In addition, we found the mean diameters of the left pulmonary artery 2.12 +/- 0.32 vs. 2.34 +/- 0.28 cm in survivors and non -survivors, respectively (p< 0.001). Mean diameters of the ascending aorta were 3.53 +/- 0.46 vs. 3.72 +/- 0.34 cm in survivors and non -survivors, respectively (p= 0.017). Conclusion: The study underscores the potential prognostic value of vascular diameters, especially in the ascending aorta and main pulmonary artery, as indicators of mortality risk in COVID-19 patients. The association between vascular dilation and severity of COVID-19, coupled with elevated D-dimer levels, suggests a link between thrombosis and vascular involvement.
- 9 March 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (5) , 1693-1701
Clinical characteristics of patients with connective tissue disease–related interstitial lung disease: a retrospective analysis
Introduction Interstitial lung disease is one of the most critical manifestations of connective tissue diseases that may cause morbidity and mortality. This study aimed to evaluate the clinical and demographic characteristics and treatment of the patients with connective tissue disease–related interstitial lung disease. Method This retrospective observational study included patients from the Gulhane Rheumatology Interstitial Lung Disease cohort between October 2016 and June 2023. The patients were assessed retrospectively. Results A total of 173 patients were included in the study with a mean age of 63.4 ± 11.9 years. The frequencies of CTD were 34.1% Sjogren’s syndrome, 30.1% rheumatoid arthritis, 25.4% systemic sclerosis, 5.8% undifferentiated connective tissue disease, 2.9% idiopathic inflammatory myositis, 1.2% mixt connective tissue disease, and 0.6% systemic lupus erythematosus in decreasing frequencies. Nonspecific interstitial pneumonia, which was the most common interstitial lung disease pattern in 103 (59.5%) patients, was most frequent among patients with SS and SSc (p < 0.001 vs. p < 0.001). Usual interstitial pneumonia was most frequent among patients with RA (p < 0.001). All patients received immunosuppressive treatment, most commonly azathioprine. 57.2% were using immunosuppressives for ILD. Six patients had mortality, and infections were the leading cause. Conclusions As a critical manifestation of connective tissue diseases, immunosuppressive treatment is indispensable in the management of interstitial lung diseases especially those at an increased risk for progression. The treatment approaches should be assessed in a patient-based way. The patients under immunosuppressive treatment should be cautiously followed for infections. Key Points • Interstitial lung disease is a noteworthy manifestation of connective tissue diseases. • The clinical findings, treatment requirements, and progression vary according to the severity of the disease. • Immunosuppressive treatment may be essential in patients with worsening symptoms, impaired pulmonary function tests, and radiological findings.
- 9 March 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 43 (5) , 1693-1701
Clinical characteristics of patients with connective tissue disease–related interstitial lung disease: a retrospective analysis
Introduction Interstitial lung disease is one of the most critical manifestations of connective tissue diseases that may cause morbidity and mortality. This study aimed to evaluate the clinical and demographic characteristics and treatment of the patients with connective tissue disease–related interstitial lung disease. Method This retrospective observational study included patients from the Gulhane Rheumatology Interstitial Lung Disease cohort between October 2016 and June 2023. The patients were assessed retrospectively. Results A total of 173 patients were included in the study with a mean age of 63.4 ± 11.9 years. The frequencies of CTD were 34.1% Sjogren’s syndrome, 30.1% rheumatoid arthritis, 25.4% systemic sclerosis, 5.8% undifferentiated connective tissue disease, 2.9% idiopathic inflammatory myositis, 1.2% mixt connective tissue disease, and 0.6% systemic lupus erythematosus in decreasing frequencies. Nonspecific interstitial pneumonia, which was the most common interstitial lung disease pattern in 103 (59.5%) patients, was most frequent among patients with SS and SSc (p < 0.001 vs. p < 0.001). Usual interstitial pneumonia was most frequent among patients with RA (p < 0.001). All patients received immunosuppressive treatment, most commonly azathioprine. 57.2% were using immunosuppressives for ILD. Six patients had mortality, and infections were the leading cause. Conclusions As a critical manifestation of connective tissue diseases, immunosuppressive treatment is indispensable in the management of interstitial lung diseases especially those at an increased risk for progression. The treatment approaches should be assessed in a patient-based way. The patients under immunosuppressive treatment should be cautiously followed for infections. Key Points • Interstitial lung disease is a noteworthy manifestation of connective tissue diseases. • The clinical findings, treatment requirements, and progression vary according to the severity of the disease. • Immunosuppressive treatment may be essential in patients with worsening symptoms, impaired pulmonary function tests, and radiological findings.
- 25 May 2023
- Published by Elsevier in Respiratory Investigation
- Vol. 61 (4) , 490-497
Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions
- 25 May 2023
- Published by Elsevier in Respiratory Investigation
- Vol. 61 (4) , 490-497
Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions
- 1 July 2021
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 17 (2) , 121-124
Effect of Pulmonary Rehabilitation on Patients With Severe and Very Severe COPD and Emphysema
- 1 July 2021
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 17 (2) , 121-124
Effect of Pulmonary Rehabilitation on Patients With Severe and Very Severe COPD and Emphysema